Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market
1. Kazia announces a $2 million PIPE agreement with institutional investors. 2. Shares priced at a 5% premium to prior closing on July 31, 2025. 3. Funds will support clinical development of leading drug programs, mainly paxalisib. 4. CEO emphasizes importance of this capital for upcoming advanced breast cancer trial data. 5. Transaction does not involve a public offering; registration is required for resale.